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1  | INTRODUC TION
Neurodevelopmental disorders encompass diverse, dynamic and 
interactive childhood-onset symptoms, which can include sensory 
deficits, motor impairments, epilepsies, intellectual disabilities and 
mental health difficulties. Until recently, the cause of each indi-
vidual's disorder was most often unknown. Now, genomic analysis 
can diagnose a specific cause in 60% of severely affected children 
(Gilissen et al., 2014), and the catalogue of genetic diagnoses asso-
ciated with neurodevelopmental disorders has rapidly expanded to 
more than 1,500 confirmed genes (https://www.ebi.ac.uk/gene2 
pheno type). This step-change in aetiological diagnosis yields new 
opportunities to understand the multi-level mechanisms contrib-
uting to each individual's difficulties and, potentially, to treat their 
underlying brain dysfunction rather than (or in addition to) their on-
the-surface symptoms.
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Abstract
In this review, we describe and discuss neurodevelopmental phenotypes arising from 
rare, high penetrance genomic variants which directly influence synaptic vesicle cy-
cling (SVC disorders). Pathogenic variants in each SVC disorder gene lead to distur-
bance of at least one SVC subprocess, namely vesicle trafficking (e.g. KIF1A and GDI1), 
clustering (e.g. TRIO, NRXN1 and SYN1), docking and priming (e.g. STXBP1), fusion 
(e.g. SYT1 and PRRT2) or re-uptake (e.g. DNM1, AP1S2 and TBC1D24). We observe 
that SVC disorders share a common set of neurological symptoms (movement disor-
ders, epilepsies), cognitive impairments (developmental delay, intellectual disabilities, 
cerebral visual impairment) and mental health difficulties (autism, ADHD, psychiat-
ric symptoms). On the other hand, there is notable phenotypic variation between 
and within disorders, which may reflect selective disruption to SVC subprocesses, 
spatiotemporal and cell-specific gene expression profiles, mutation-specific effects, 
or modifying factors. Understanding the common cellular and systems mechanisms 
underlying neurodevelopmental phenotypes in SVC disorders, and the factors re-
sponsible for variation in clinical presentations and outcomes, may translate to per-
sonalized clinical management and improved quality of life for patients and families.
K E Y W O R D S
cerebral visual impairment, epilepsy, intellectual disability, mental health, movement 
disorders, Synaptic vesicle cycle
This Review is part of the special issue 
“Presynaptic Dysfunction and Disease”.  
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There are, however, major challenges inherent to these goals. 
One challenge is the extreme rarity of each genetic diagnosis. A 
second challenge is the complexity of neurological, cognitive and 
behavioural symptoms which vary between individuals and within 
individuals over time, and may be relatively non-specific reflections 
of underlying neurobiological disruption. One strategy with po-
tential clinical and scientific utility is to consider groups of genetic 
diagnoses which converge on shared physiological functions, and 
are thus expected to lead to a similar spectrum of symptoms via 
common underlying mechanisms. Numerous data-driven analyses 
have implicated discrete functional networks in neurodevelopmen-
tal disorders, such as chromatin regulation, post-synaptic signalling 
and cytoskeletal architecture (van Bokhoven, 2011; Sullivan, De 
Rubeis, & Schaefer, 2019). Investigating the phenotypic correlates of 
functional networks could improve diagnostic confidence, because 
network-specific “phenotypic signatures” (either overt symptoms or 
covert endophenotypes) could reduce the number of genetic test 
results classified as variants of uncertain significance. Network-
informed phenotyping could assist in prognostication by expanding 
the range of types, severities and natural histories of symptoms. 
Functional networks may also guide clinical management via selec-
tion of therapies that are safe and effective network-wide, or novel 
network-targeted treatments. On the other hand, understanding 
phenotypic variation within a functional network is also clinically rel-
evant, enabling individualized prognosis and identification of modifi-
able factors influencing the severity of outcomes.
One such functional network is synaptic vesicle cycling (SVC). 
SVC genes facilitate and control neurotransmitter release and recy-
cling, and are thus critical for synaptic transmission and plasticity, 
underlying in-the-moment cognitive processes and adaptive cog-
nitive development. Rare, high penetrance variants in many SVC 
genes (SVC disorders) have now been diagnosed in individuals with 
neurodevelopmental disorders (Table 1). In this article we apply the 
functional networks framework to describe the spectrum of neu-
rodevelopmental phenotypes associated with SVC disorders. Our 
primary objective is to systematically collate the published clinical 
literature on SVC disorders, to highlight the extent of similarity 
across the network, and important differences between and within 
disorders. Our secondary objective is to provide a quantitative com-
parison of reported neurodevelopmental phenotypes between SVC 
disorders and other monogenic developmental disorders. To achieve 
this, we have analysed open access data from the DECIPHER da-
tabase (https://decip her.sanger.ac.uk/). Considering both sources of 
information, we discuss reasons for phenotypic similarity and varia-
tion within the SVC disorders network.
2  | METHODS
This review encompasses SVC disorders listed by Bonnycastle, 
Davenport and Cousin in this issue (2020), supplemented by ad-
ditional disorders with strong evidence for pathogenicity and di-
rect involvement in SVC physiology. Defining the boundaries of a 
functional network is not straightforward, and we recognize that 
some SVC genes will have additional functions which may influence 
phenotype, for example involvement in post-synaptic physiology or 
embryonic neurodevelopment. Many other genes will have indirect 
impact on the SVC, for example via regulation of gene expression 
and post-translational modification.
We conducted a PubMed search (terms: ‘gene name’ and 
VARIANT or MUTATION and NEURODEV* or DISORDER) to iden-
tify all publications reporting pathogenic or likely pathogenic vari-
ants in each SVC gene alongside clinical phenotype data (ideally at 
individual patient level). Although we have attempted to collate a 
comprehensive literature list, this is likely incomplete especially for 
less rare disorders. Where multiple publications have been pooled 
into a case review, we report the data from the reviewed case se-
ries and aim not to double-report individual cases. We have not con-
ducted independent analysis of the likely pathogenicity of reported 
variants. For ultra-rare diagnoses where only 1 or a small handful of 
cases have been reported to date, it is important to maintain cau-
tion in presuming pathogenicity. Moreover, it is well-recognized that 
some SVC genes, for example calcium channel subunits, can be rel-
atively tolerant of coding sequence variation, and assigning patho-
genicity to variants (especially missense variants) is challenging. For 
copy number variants, definitive evidence implicating a dosage-sen-
sitive SVC gene as causative of phenotype is often lacking.
To systematically collate reported phenotypes across publications 
and across genes, we designed a data extraction spreadsheet (avail-
able from corresponding author on request). Tables 2 and 3 compress 
publication-level data to provide a summary overview of reported neu-
rodevelopmental phenotypes for each SVC disorder. This simplified 
summary should not devalue the nuanced and detailed work within 
each individual paper within the reference list. The quantity and gran-
ularity of phenotype reporting varies widely between publications, 
hence empty table cells could mean that a phenotype is truly not ob-
served in patients, or has not been assessed or documented in publica-
tions, that is we can only evaluate positive evidence for the presence 
of phenotypes, and cannot interpret absence of evidence as evidence 
of absence. The vast majority of reviewed publications represent ret-
rospective case note reviews, rather than comprehensive evaluations 
applying standardized assessment methods. A further limitation of 
the literature is that terminology is not consistently applied, for exam-
ple Human Phenotype Ontology (Kohler et al., 2017) or International 
League Against Epilepsy classifications (Fisher et al., 2017) are infre-
quently used, reducing comparability of reporting across studies.
To complement this literature review exercise, we present 
quantitative analysis of phenotypes reported in DECIPHER (open 
access) as of December 2019. DECIPHER is used by the clinical 
community to share and compare phenotypic and genotypic data 
(Firth et al., 2009). The DECIPHER database currently contains 
data from 36,122 patients who have given consent for broad data 
sharing. To facilitate our group-wise analysis, data were shared 
from DECIPHER in bulk via a data access agreement with the 
University of Cambridge. Neurodevelopmental Human Phenotype 
Ontology terms were selected via text search and grouped into four 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































218  |     JOHN et al.
categories (developmental delay/ intellectual disability, movement 
disorders, epilepsies, visual impairments) reflecting the symptom 
domains most frequently reported in the SVC disorders literature 
review. There is likely under-reporting of phenotype presence within 
DECIPHER, since there is no requirement to positively affirm every 
possible phenotype when reporting a variant to the database. Hence 
frequencies should be interpreted in comparative terms, and not as 
prevalence statistics. It should also be noted that many individual 
patients within DECIPHER have more than one sequence variant. 
Reported phenotype frequencies were compared between se-
quence variants in SVC genes and all other developmental disorder 
genes (not copy number variants; classified by the uploading clinical 
team as pathogenic, likely pathogenic or uncertain) (Figure 1). SVC 
subprocess variants within DECIPHER were also compared, grouped 
according to Bonnycastle, Davenport, and Cousin (2020) according 
to predominant roles in vesicle trafficking, clustering and scaffold-
ing, docking and priming, fusion and endocytosis.
In the following sections, we summarize and discuss the results 
of our literature review and DECIPHER analysis, organized by phe-
notype domain, ordered by the frequency of phenotype reporting in 
DECIPHER. For each phenotype domain, we provide a description 
of symptoms, discuss frequency and variability in symptoms within 
SVC disorders, and highlight genotype–phenotype correlations and 
neural systems mechanisms where these are known.
3  | DE VELOPMENTAL DEL AY AND 
INTELLEC TUAL DISABILIT Y
Intellectual disability (ID) is defined as significant and persistent im-
pairments in cognitive ability and adaptive function, with onset be-
fore the age of 18 years (APA, 2013). ID is commonly preceded by, 
though not an inevitable successor to, delay in achieving develop-
mental milestones (DD), either globally or selectively within motor, 
communication and social domains. DD and ID are the hallmark 
functional consequences of any disruption or constraint on brain 
development; they are of high clinical importance in predicting the 
needs of patients and families, but low specificity with regard to ae-
tiology and mechanism.
Our literature review indicated that DD/ID is reported in all SVC 
disorders, but varies in prevalence from being universally reported 
in around two thirds of disorders, to only sometimes or rarely re-
ported in the remainder. This was corroborated within DECIPHER, 
where DD or ID was reported for 75% of SVC cases, in comparison 
to 63% of non-SVC cases (2(1) = 14.49, p < .001). Determining the 
true prevalence of DD/ID in association with SVC disorder variants 
is difficult, because these phenotypes are the primary ascertain-
ment criteria for many individuals referred for genetic testing, but 
are exclusion criteria for some cohort studies focused on specific 
phenotypes, for example autism (Nakamura et al., 2008) or epilepsy 
(DiFrancesco et al., 2019). Across the SVC disorders catalogue, DD/
ID varies in severity from mild to profound. For some genes, for ex-
ample CPLXN1, SYT1 and VAMP2, DD/ID has always been reported 
as severe or profound. However, for the majority of SVC disorders, 
severity of DD/ID can range from mild to profound. There are a num-
ber of caveats here, one being that initial discovery of novel genetic 
disorders tends to take place in severely affected individuals; once a 
larger number of cases are identified genotype-first, it is common to 
observe a broadening of the severity range for DD/ID. In addition, 
clinical literature does not consistently apply the same criteria for 
classifying ID severity, and this classification can change over time 
within individuals.
It is also interesting to consider SVC disorders, notably PRRT2, 
which are not usually associated with DD/ID. The cognitive con-
sequences of PRRT2 variants have received limited attention to 
date, but include learning disabilities and impaired fine motor skills, 
alongside neuropsychiatric difficulties in some individuals (Djemie 
et al., 2014). One possibility is that PRRT2 variants exerting a more 
F I G U R E  1   Comparison of 
neurodevelopmental phenotype 
frequencies for SVC and non-SVC 
disorders. Neurodevelopmental 
phenotype frequencies for open access 
sequence variants in SVC and non-
SVC genes, reported in the DECIPHER 
database as of December 2019. See text 
for statistical analyses
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severe impact on SVC fusion capacity may be lethal, hence de novo 
cases are rarely diagnosed and inherited cases may represent the 
tolerable mutation spectrum. However, it is also possible that co-oc-
curring cognitive and mental health difficulties arise because of 
secondary causes in some individuals with PRRT2 variants (such as 
second genetic hits, or consequential to infantile epilepsy), and that 
PRRT2 dysfunction is not directly related to cognitive impairment, 
for reasons not currently understood. Discovering why PRRT2-
related SVC disruption usually results in relatively intact cognitive 
development may be relevant to other SVC disorders.
To date, there are very few studies that have employed standard-
ized assessments to characterize DD/ID in more detail within SVC 
disorders (either observational methods, or direct assessment using 
neuropsychological tests feasible for individuals with milder im-
pairments). We reported questionnaire-based assessment of adap-
tive function and behavioural characteristics in 14 individuals with 
STXBP1 variants, and found that on average global impairment was 
more severe than other monogenic neurodevelopmental disorders, 
with particularly severe restriction to receptive language, social skills 
and fine motor abilities (O'Brien et al., 2019). Several other authors 
have reported that speech abilities may be disproportionately af-
fected in SVC disorders. For example GDI1 dosage variants have been 
associated with pronounced speech delay, even among individuals 
with milder ID or no ID (Ward et al., 2018). Similarly, speech delays 
are present in over 90% of individuals with NRXN1 deletions, even 
among those with normal range intelligence (Al Shehhi et al., 2019; 
Bena, Bruno, & Eriksson, 2013; Dabell, Rosenfeld, & Bader, 2013). 
However, comparative longitudinal research is needed to determine 
whether the trajectories of communication development are more 
homogeneous and severe among the SVC disorders group than ex-
pected for any other neurodevelopmental disorders group.
The extent to which SVC diagnoses are associated with progres-
sive neuropathology and decline in cognition and adaptive function 
over time cannot yet be concluded (although it has been noted for 
some conditions, e.g. dominant KIF1A variants). This potential for 
decline is an understandable worry for affected individuals and their 
families, however, recognizing dynamic or deteriorating symptoms 
may help to define treatment priorities and identify opportunities 
for positive clinical impact.
Overall, current data indicate that while DD/ID is a common 
functional consequence of SVC disruption, it is not inevitable, and is 
variable between individuals and over time. This variability prompts 
the major questions of how SVC disruption constrains the emer-
gence of cognitive capacities, and which factors predict and mediate 
variation in cognitive outcomes. Our literature review did not high-
light a strong association between SVC subprocesses and ID preva-
lence or severity, and within Decipher we did not observe significant 
differences between subprocess groups in the frequency of DD/
ID (2(4) = 5.18, p = .269). We reviewed individual disorder stud-
ies for evidence of modifying factors. There is currently no positive 
evidence that the presence or severity of epilepsy is a major medi-
ating factor for DD/ID within SVC disorders, for example within the 
STXBP1 group in which both epilepsy severity and DD/ID severity 
are highly variable (Stamberger, Nikanorova, & Willemsen, 2016). 
Second-hit genomic modifiers of outcome have yet to be explored 
in any SVC disorder.
A small number of genotype–phenotype studies indicate that 
variation in molecular disruption can underlie variation in cogni-
tive outcomes within SVC disorders. At the most basic level, both 
heterozygous and biallelic loss of function mutations have been 
reported for some genes (e.g. STXBP1, CACNA1A, PRRT2); for 
these ultra-rare cases, homozygosity is associated with ID severity 
(Delcourt, Riant, & Mancini, 2015; Lammertse et al., 2020; Reinson, 
Oiglane-Shlik, & Talvik, 2016). Domain-specific predictors of ID se-
verity have been reported for DNM1, where PH domain variants are 
associated with a milder phenotype than GTPase or middle domains 
variants (Nakashima, Kouga, & Lourenco, 2016; von Spiczak, Helbig, 
& Shinde, 2017). TRIO missense mutations at spectrin sites are as-
sociated with more severe ID compared to missense mutations at 
GEFD1 site or nonsense mutations, translating to hyper/hypoactiva-
tion of RAC1 (Barbosa et al., 2020). However, SVC physiological cor-
relates of these genotype–phenotype associations remain unknown. 
For SYT1, there have been early attempts to relate the severity of 
vesicle release dysfunction to patients’ functional outcomes includ-
ing ID. Baker et al. (2018) showed that variants I368T and N371K 
have a quantitatively more severe impact on rate of vesicle release 
than variants D366E and D304G, mirroring patients’ severity of 
cognitive outcome. These results have recently been replicated in 
independent experiments and extended to show a graded domi-
nant-negative effect of SYT1 dysfunction on post-synaptic activa-
tion (Bradberry et al., 2020). Building on these findings, it is possible 
that impairment to SVC kinetics and neurotransmission efficiency 
(via diverse molecular mechanisms specific to each gene) could me-
diate cognitive impairment and influence ID severity across the SVC 
functional network. In summary, to prognosticate regarding ID se-
verity for individuals with SVC disorders, it is necessary to go be-
yond the gene to consider the specific mutation and its consequence 
on protein function and physiology.
4  | EPILEPSY
A seizure is a transient occurrence of symptoms and/or signs be-
cause of abnormal excessive or synchronous neuronal activity in the 
brain, and an individual is defined as having epilepsy if they have an 
enduring predisposition to seizures, having experienced at least one 
(Fisher et al., 2014). Diagnosis rests on careful assessment of clinical 
phenomena and supporting electrophysiological evidence from elec-
troencepalography (EEG). Epilepsy classification now encompasses 
seizure types, co-morbidities and aetiologies (Fisher et al., 2017), 
with the aim of better prognosticating and targeting treatments to 
reduce seizure frequency, reduce risk of life-threatening complica-
tions, reduce risk of neurotoxicity secondary to prolonged seizure 
activity and hypoxia (status epilepticus), and minimize side-effects 
of anti-epileptic drugs especially when used in combination for pro-
longed periods. Understanding epilepsy from a genetic perspective 
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is clearly important, if knowledge of associated epilepsy phenotypes 
and mechanisms could improve epilepsy management and impact on 
long-term outcomes. However, seizures are a complex manifesta-
tion of many interacting neurobiological factors including age, brain 
structural integrity, metabolic status and environmental triggers (e.g. 
temperature, diet, infection, sensory stimulation). Thus predicting an 
individual's seizure risk, seizure types, treatment response and likeli-
hood of remission based on genetic diagnosis alone may not be re-
alistic. However, there is potential benefit in exploring whether SVC 
disorders share seizure susceptibility mechanisms and whether this 
has implications for epilepsy management.
Our literature review found that epilepsy has been diagnosed in 
at least some individuals with 27 out of 33 SVC disorders. Epilepsy 
is a universal feature in 5 SVC disorders, and for the remainder prev-
alence of epilepsy is variable (from rare to affecting the majority of 
individuals). It is also notable that some SVC disorders have never 
been associated with seizures to date (e.g. RIMS1/3 and SYT1), de-
spite electrophysiological abnormalities on EEG. Elevated risk of 
epilepsy in comparison with other developmental disorders was con-
firmed via DECIPHER analysis: seizures or epilepsy were reported 
for 35% of SVC variants compared with 17% of non-SVC variants (2
(1) = 46.98, p < .001). Establishing the true prevalence of epilepsy is 
complex, because of the age-dependent nature of seizures—some 
genes (notably PRRT2) are associated with a typical infantile age of 
seizure onset followed by remission, whereas others are associated 
with unpredictable age of onset and prognosis (meaning that sei-
zures may not be present at the time of genetic diagnosis and re-
ported in the literature or to DECIPHER). There is also a likely bias 
towards ascertainment for epilepsy-affected individuals in genetic 
discovery cohorts. Over time, it is becoming clear that some disor-
ders initially associated with severe and persistent epilepsy risk (e.g. 
STXBP1) are actually associated with a much more variable epilepsy 
phenotype, which can remit or not present until older age. However, 
it does appear that SVC disorders carry an elevated seizure suscep-
tibility, in keeping with the presumed electrophysiological origins of 
neurodevelopmental symptoms.
Epilepsy phenotypes reported across the SVC disorders group 
and within each individual disorder are highly diverse, encompassing 
all types of focal-onset and generalized seizures, that is SVC disrup-
tion can disturb local or global excitability, leading to a myriad of 
seizure phenomena. What is less clear (and beyond the scope of this 
review) is whether the pathophysiology underlying vulnerability to 
seizures, and the mechanisms of seizure initiation, progression and 
termination, are common and distinct to SVC disorders. Some clues 
may come from EEG characteristics. Epileptiform EEG features ob-
served in SVC disorder individuals correlate with observed seizure 
phenotypes. However, interictal abnormalities and background EEG 
abnormalities point towards distinctive and unusual electrophysi-
ological properties, including bursts of low-frequency oscillations, 
which have been observed across a number of disorders (AP4 sub-
unit variants, STXBP1, STX1B, SYT1 and DNM1). However, the rela-
tionships between these abnormal synchronizations and seizure risk 
are not clear. This is particularly unclear for variants in SYT1 in which 
profoundly abnormal EEG oscillations are characteristic, but seizures 
have not been reported for any patient to date.
Genotype–phenotype studies are potentially informative of 
mechanisms contributing to variable epilepsy risk across the SVC 
spectrum. For example Balestrini, Milh, and Castiglioni (2016) re-
ported more severe and drug-resistant epilepsies in individuals with 
frameshift, nonsense and splice site variants versus missense vari-
ants in TBC1D24. In contrast, dominant-negative missense variants 
in SNAP25, DNM1 and calcium channel subunits are associated with 
severe epilepsy phenotypes (Helbig et al., 2018; Heyne et al., 2018; 
von Spiczak et al., 2017). For some genes, a domain-specific gen-
otype–phenotype correlation for epilepsy has been detected, for 
example VAMP2 C-terminal region (Salpietro et al., 2019). There is 
likely to be diversity of mechanisms by which genotypes mediate 
variation in epilepsy risk within SVC disorders. For example epilep-
sy-associated mutations may impact on early neurite development, 
as has been shown for SYN1 (Fassio et al., 2011), TBC1D24 (Balestrini 
et al., 2016) and STXBP1 (Yamashita, Chiyonobu, & Yoshida, 2016), 
whereas seizure risk might be lower for variants impacting only on 
post-embryological SVC function.
We explored within the DECIPHER dataset whether SVC sub-
processes could predict prevalence, and potentially highlight epilep-
sy-relevant mechanisms. Subprocess groups differed significantly 
in frequency of epilepsy reporting (2(4) = 16.11, p = .003), being 
highest in the docking and priming subgroup, and lowest in the clus-
tering group (where prevalence was in line with non-SVC variants). 
The docking subgroup is dominated by STXBP1 variants, hence as-
certainment and reporting bias should be considered as a potential 
limiting factor in interpreting this observation. It has been reported 
that STXBP1 haploinsufficiency reduces inhibitory neurotransmis-
sion of GABA-ergic interneurons (Kovacevic et al., 2018), hence fu-
ture studies of seizure mechanisms in SVC disorders may need to 
focus on selective impact on inhibitory neurotransmitter systems 
(either embryological neurodevelopment or postnatal function). In 
addition to selective impact on SVC subprocesses, involvement in 
trans- and post-synaptic zone processes may contribute to variable 
epilepsy risk. Until mechanisms are better understood, epilepsy 
management in SVC disorders is likely to remain empirically driven 
by epilepsy phenotypes and safety profiles, and a significant propor-
tion of individuals will continue to suffer from refractory seizures.
5  | VISUAL IMPAIRMENTS
Visual function is critical to accessing and interacting with the envi-
ronment. Any impairments to vision (whether arising from the eye, 
visual tracts, primary visual cortex or vision-relevant neural systems) 
will influence diverse aspects of learning, adaptive function and social 
interaction. In the absence of structural eye abnormalities or retinopa-
thy (both rare among individuals with SVC disorders) abnormal visual 
behaviour is presumed to arise from Cerebral Visual Impairment (CVI). 
CVI is itself a broad descriptive spectrum encompassing diverse vis-
ual processing problems, which can be very difficult to assess in the 
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context of extensive cognitive impairments. CVI commonly co-occurs 
with developmental motor impairments, for example in the context of 
periventricular white matter pathology secondary to prematurity and 
hypoxia. CVI is less well documented in genetic neurodevelopmental 
disorders, but it is increasingly recognized that some genetic disorders 
are associated with higher prevalence of CVI than expected for level 
of global neurodevelopmental impairment (Bosch et al., 2016). If SVC 
disorders are associated with CVI (alongside motor and cognitive im-
pairments, or as an isolated problem), this is important to recognize 
because adapting individuals’ visual environment and educational 
support can promote many other positive aspects of development, 
in particular communication skills and emotional stability. Ultimately, 
strategies to directly improve cerebral visual information processing 
could also be beneficial.
Our literature review highlighted a visual phenotype in 21 out of 
33 SVC disorders. We noted that visual phenotypes were reported 
infrequently for disorders of docking and priming, but were reported 
for all disorders of endocytosis and almost all disorders of fusion 
and trafficking. Moreover, there appeared to be some broad differ-
ences in the types of visual symptoms most commonly associated 
with SVC subprocesses—for disorders of trafficking, fusion and en-
docytosis, eye movement abnormalities and CVI appear to be espe-
cially common. This summary of the literature was mirrored within 
the DECIPHER database—we found that visual phenotypes were re-
ported more commonly for SVC variants than non-SVC variants (29% 
versus 21%; 2(1) = 7.98, p = .005). We also detected contrasting 
frequencies of visual impairments between SVC subprocess groups, 
being especially common within the endocytosis subprocess group 
(>40%), although subprocess groups did not differ significantly over-
all (2 (4) = 9.03, p = .060). Within DECIPHER, most endocytosis-re-
lated variants are within DNM1, CLTC and RAB11A, and this reported 
frequency of visual impairments is consistent with our review of the 
literature on these three genes. One potential reporting bias to note 
is that visual impairments may be more commonly assessed if they 
have already been noted in the published literature.
Why might it be the case that SVC disorders are associated with 
an elevated rate of CVI in comparison to other neurogenetic disor-
ders? One possibility could be co-occurrence with movement disor-
ders, either because these two phenotype categories arise from an 
overlapping set of neuroanatomical systems functionally susceptible 
to SVC disruption (e.g. sensorimotor integration cortex and subcor-
tical-cortical feedback systems), or because motor impairments have 
a consequential impact on eye movement control and higher-order 
visual development. Within the SVC disorders group in DECIPHER, 
there is only marginal difference in the rate of reported visual im-
pairment between individuals with (33%) and without (28%) a move-
ment disorder, indicating that these two phenotype domains are 
not tightly associated. Another possibility is that visual impairments 
could co-occur with epileptogenic abnormalities of excitability, or 
arise as a secondary consequence of seizure activity. However, the 
rate of reported visual impairment was identical (29%) among SVC 
disorder individuals in DECIPHER with and without reported epi-
lepsy. In summary, visual impairment appears to be an independent 
symptom domain within the SVC group. While multiple aspects of 
SVC physiology can affect vision, the impact of disrupted endocyto-
sis on sensory plasticity and vision-relevant neural systems develop-
ment may be a particularly interesting avenue to explore.
6  | MOVEMENT DISORDERS
Movement disorders (MD) encompass many different types of ab-
normal involuntary motor symptoms including dystonia, chorea-
athetosis, myoclonus, tremor, ataxia and stereotypies. Symptoms 
can be continuous or paroxysmal, acute or chronic, hypokinetic or 
hyperkinetic, part of a complex neurodisability or isolated. Although 
MD and delayed motor skill acquisition are not synonymous, in-
voluntary movements can impede practical activities ranging from 
ambulation to fine motor skills, and have knock-on consequences 
for cognitive and social development, educational inclusion and 
mental health. It can be difficult to distinguish MD from epileptic 
or behavioural abnormalities, especially when these co-occur within 
the same individual. For example it may not always be possible to 
distinguish between hyperkinetic involuntary movements and at-
tention deficit hyperactivity disorder (ADHD), or stereotypies and 
autism-related repetitive mannerisms, since there is no definitive 
discriminating neurobiological test. Discriminating between epilep-
tic and non-epileptic origins of symptoms (e.g. myoclonic movement 
disorder versus myoclonic seizures) can usually be resolved via EEG. 
An additional complicating factor for ascertaining the prevalence of 
movement disorder is that symptoms vary across the lifespan within 
individuals, a common pattern being infant hypotonia followed by 
childhood dystonia and chorea, and later progression to hypertonia 
and hypokinesia. In general terms, MD arise from abnormal cortical-
subcortical network activity arising from dysfunctional basal ganglia 
or cerebellar control systems (and/ or cortex in case of myoclonus). In 
many MD aetiologies, structural damage or white matter pathology 
can be identified on magnetic resonance imaging (MRI). However, as 
listed in Table 3, subcortical structural pathology (either congenital 
or degenerative) is not reported on routine MRI for any SVC disor-
der, and only mild and non-specific cerebral or cerebellar atrophy or 
white mature maturational differences have been reported, indicat-
ing a functional rather than structural origin to MD symptoms.
At least one type of movement disorder has been reported in 
26 out of 33 SVC disorders, making it one of the most common 
presenting neurological features across the SVC functional net-
work. Literature review indicated that disorders of clustering and 
scaffolding carry lower risk of MD (although with exceptions such 
as KIF1A). Disorders of docking and priming, including STXBP1, are 
rarely associated with severe dystonia and dyskinesia, but tremor 
and ataxia are common. For disorders of fusion and endocytosis, 
mixed involuntary movement symptoms are reported in association 
with almost every gene, but vary in frequency, type and severity 
within disorders. PRRT2 is perhaps an exception, in that variants are 
associated with a very characteristic movement disorder phenotype 
(paroxysmal kinesigenic dyskinesia, PKD—recurrent brief attacks 
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of involuntary movements, triggered by movement), but also other 
episodic phenomena including hemiplegic migraine and ataxia (in-
triguingly overlapping with CACNA1A). Dangerous escalations of 
sustained involuntary movements (known as dystonic storms, sta-
tus dystonicus or oculogyric crises), which can be associated with 
autonomic and cardiorespiratory collapse, are infrequently reported 
across the SVC disorders spectrum.
Within the DECIPHER database we searched for reporting of 
dystonia, chorea, tremor, ataxia, gait disturbance and stereotypies, 
finding that at least one of these symptoms was reported for 26% 
of SVC gene variants compared with 11% of non-SVC variants (2
(1) = 41.25, p < .001). Hence, although MD are not specific to SVC 
genes, and do not affect all individuals, this phenotype category is 
significantly enriched in association with SVC disorders. In keeping 
with our overview of the literature, we found significant differ-
ence in likelihood of MD reporting between SVC subprocesses (2
(4) = 10.03, p = .040), but with risk being highest for the docking and 
trafficking subgroups. Looking in more detail, we found that the high 
rate of MD for these two subgroups represents tremor, ataxia and 
stereotypies, whereas dystonia is reported relatively frequently for 
fusion and endocytosis genes. This suggests that disturbance to dif-
ferent aspects of SVC impacts on different neural systems necessary 
for motor control.
There are few genotype–phenotype studies focused on move-
ment disorder symptoms within SVC disorders. Despite extensive 
investigation and the presence of recurrent variants, PRRT2 variants 
do not appear to predict PKD severity, with high levels of intra-fa-
milial variation including non-penetrance (Valtorta, Benfenati, Zara, 
& Meldolesi, 2016). For SYT1, dyskinetic movement disorder was 
reported in association with some, but not all recurrent mutations 
(observed in multiple individuals with I368T and N371K, but not 
D366E) which may reflect a threshold effect or graded impact of 
disruption to exocytosis (Baker et al., 2018; Bradberry et al., 2020). A 
single patient with dyskinetic movement disorder has been reported 
with a de novo P814L variant in UNC13A (Lipstein et al., 2017). 
Electrophysiological studies in murine neuronal cultures and func-
tional analysis in C. elegans showed that that the UNC13A variant 
causes a distinctive dominant gain of function characterized by an 
increased fusion rate of vesicles. Hence variants in two fusion genes 
(SYT1 and UNC13A) seem to have opposing effects on neurotrans-
mission kinetics, leading to a similar movement disorder, indicating 
the complexity of presynaptic regulation of motor control.
In summary, both literature review and DECIPHER analysis high-
light the elevated prevalence of MD in SVC disorders in comparison 
to other monogenic causes of neurodevelopmental disorder. This 
confirms that subcortical-cortical network function is dependent 
on tight pre-synaptic control of neurotransmission. However, the 
variation in symptom prevalence and types, between and within 
disorders, highlights the complexity of motor control and potential 
availability of compensatory mechanisms capable of buffering SVC 
dysfunction. The high frequency of tremor and ataxia in association 
with vesicle trafficking may reflect broader transport defects influ-
encing white matter tract development (indeed KIF1A is relatively 
highly expressed within white matter). For docking genes such as 
STXBP1, a cerebellar mechanism appears more likely, based on rela-
tively high regional expression. The specific neural systems origin of 
involuntary movements in individuals with fusion and endocytosis 
disorders remain to be discovered. One possibility is that midbrain 
dopaminergic cells may be selectively dependent on SVC disorder 
genes (e.g. lacking synaptotagmin isoform expression to compensate 
for SYT1 dysfunction), leading to inefficient dopaminergic signal-
ling and basal ganglia function. Another possibility is that abnormal 
temporal dynamics of neurotransmission has a system-specific im-
pact on neural networks underlying voluntary control of movement. 
Another explanation is that SVC disorders are associated with a gen-
eral state of hyper-excitability, over-tipping the balances between 
action execution and action inhibition. Defining the mechanisms un-
derlying these symptoms is important, as each mechanism suggests 
a different mode of treatment, for example specific pharmacological 
targeting of a neurotransmitter system, or specific anatomical tar-
geting via deep brain stimulation. Defining these mechanisms and 
identifying safe and effective treatments for MD in SVC disorders 
could be relevant to later onset degenerative conditions resulting 
in convergent symptom profiles, and involving a functionally simi-
lar genetic spectrum in familial and early onset cases (most notably 
SYNJ1 and SNCA).
7  | MENTAL HE ALTH
Individuals with neurodevelopmental disorders carry an elevated 
vulnerability to disturbances of emotion regulation, social inter-
action and behavioural control, resulting in higher rates of mental 
health difficulties across the lifespan (Cooper, Smiley, Morrison, 
Williamson, & Allan, 2007; Emerson & Hatton, 2007). These difficul-
ties are important because they have major impact on quality of life 
for patients and their families, and predict long-term support needs. 
However, mental health difficulties are not an inevitable conse-
quence of ID, and do not in general correlate with severity of global 
cognitive impairments. Each mental health symptom (such as anxi-
ety, mood disturbance or social withdrawal) can arise from a host of 
different neurobiological and cognitive mechanisms, and the symp-
toms arising from an underlying vulnerability can be equally diverse. 
However, it may be that individuals sharing a genetic diagnosis, or in 
this case sharing SVC network disruption, also share a more homo-
geneous set of underlying vulnerabilities and associated symptoms. 
To better understand and manage mental health difficulties in indi-
viduals with SVC disorders, it would be ideal to integrate informa-
tion about each individual's genetic diagnosis, their neurobiological 
vulnerabilities and cognitive impairments, and their environmental 
and interpersonal risk factors.
Within the reviewed literature on SVC disorders, childhood-on-
set psychiatric phenotypes (predominantly autism or ADHD) have 
been reported in 24 out of 33 SVC disorders (Table 2). As expected, 
neither of these behaviourally defined diagnoses is universally re-
ported for all cases of any SVC disorder (excepting studies where 
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autism was the ascertaining criterion). Within DECIPHER, mental 
health phenotypes are not extensively documented, but we did not 
find that autism was reported more frequently for the SVC disorders 
group (7.36%) in comparison to all other disorders (8.46%). However, 
the complexity of SVC-associated neurodevelopmental phenotypes 
is likely to introduce several challenges in the assessment and diag-
nosis of social, emotional and behavioural difficulties. For example 
cerebral visual impairment and autism are both frequently reported 
in association with DNM1 variants—determining the origins and sig-
nificance of symptoms such as abnormal eye contact or auditory 
hypersensitivity may be difficult if not impossible in this context. 
Similarly, it can be very difficult in clinical practice to discriminate 
between neurological symptoms (such as hyperkinetic involuntary 
movement disorder or motor stereotypies), and mental health symp-
toms (such as hyperactivity and repetitive behaviours), all of which 
are common features of SVC disorders. In fact, these different termi-
nologies may reflect identical symptom phenomenon, or disruption 
to the same neurobiological mechanisms, but varying in degree. It 
is noteworthy that mental health diagnoses appear to be especially 
common in SVC disorders associated with a milder range of ID (such 
as TRIO, NRXN and CLTC variants). This may reflect a greater clin-
ical sensitivity to atypical behavioural profiles in these groups as 
compared to severe and profound impairment, or less comprehen-
sive support and resources available to those with milder ID, or true 
specificity.
The majority of SVC gene discovery studies have focused on 
children, hence the longer term psychiatric morbidity across the net-
work has yet to be established. This is especially true for de novo 
disorders where affected individuals across multiple generations of a 
family will not be available. Where adult cases have been described, 
for example de novo variants in TRIO (Barbosa et al., 2020) or inher-
ited variants in GDI1 (Ward et al., 2018), it is clear that emotional 
and social vulnerabilities in individuals with SVC disorders do extend 
beyond the childhood and adolescent periods. Indeed, a wide range 
of later onset psychiatric diagnoses have been reported across 21 
different SVC disorders, such as depression, anxiety, obsessive com-
pulsive disorder and psychosis.
Each psychiatric diagnosis encompasses a diverse range of 
symptoms and impairments (for autism—diverse aspects of social 
function plus restricted and repetitive behaviours; for ADHD—in-
attention, hyperactivity and impulsivity; for mood disorders—highly 
diverse emotional and somatic symptoms). Current literature on SVC 
disorders does not enable us to establish associations with specific 
symptom dimensions, because few studies have reported this level 
of information, or compared SVC disorders to other neurodevelop-
mental disorder groups. Self-injury, agitation and aggression can be 
particularly distressing and challenging for patients and carers, and 
appear to be relatively prevalent among the SVC disorders group. 
More positively, we found that strong social motivation and enjoy-
ment of family relationships was a frequent characteristic of indi-
viduals with STXBP1 variants, and distinguished this group from 
other individuals with non-SVC disorders and ID of similar severity 
(O'Brien et al., 2019). Future studies are required to determine if 
these features (both problematic and positive) are observed more 
commonly among individuals with SVC disorders than in other 
groups with severe ID, visual impairments and movement disorders.
We cannot identify any study to date which provides evidence 
for genotype–phenotype correlations within an SVC disorder for the 
presence or specific characteristics of autism or psychiatric disor-
ders. Our literature review did not highlight any clear associations 
between SVC subprocesses and likelihood of mental health manifes-
tations. Nor was there sufficient reporting of psychiatric phenotypes 
within the DECIPHER database to meaningfully relate SVC subpro-
cesses to this clinical domain. Investigating the neurodevelopmental 
pathways from SVC disturbance to mental health difficulties could 
be of great clinical value for individuals with SVC disorders, and for 
a proportion of individuals in the general population with similar 
symptoms, arising via a similar mechanistic pathway.
8  | CONCLUDING COMMENTS
In this review we have discussed the neurodevelopmental fea-
tures of SVC disorders, organized by symptom domains. In reality 
it is unusual to observe isolated symptoms from a single domain—
most individuals will experience a complex combination of interact-
ing symptoms and impairments across domains, which will change 
over time. Although no single symptom discussed in this review is 
unique or pathognomonic, in combination they may be indicative of 
a possible SVC disorder. The specificity of these observations will 
be increased if SVC disorders can be compared to other synaptic 
disorders, or to other groups presenting with similar neurodevelop-
mental phenotypes, rather than all genetic causes of developmental 
disorder combined. Physical complications involving the gastrointes-
tinal, respiratory and autonomic systems have not been discussed 
here—they are reported in a number of SVC disorders, usually in 
association with severe neurodisability, and it is not clear whether 
they occur more frequently than expected for global neurodevelop-
mental impairment. Peripheral neurological symptoms have also not 
been surveyed.
We are currently witnessing the first generation of SVC disorder 
diagnoses—while variants in these genes must always have occurred, 
only a small number of diagnoses have yet been made, and only in 
the limited economic and cultural circumstances where genomic 
testing is currently available. Hence we are at a very early stage of 
documenting the complete clinical spectrum, and important uncer-
tainties remain. Prospective natural history studies are needed to 
obtain a comprehensive phenotypic evidence-base which can assist 
with clinical interpretation of variants, prognostication and manage-
ment. Families and clinicians are increasingly motivated to integrate 
genetic diagnosis with each individual's unique phenotypic kaleido-
scope, to harness knowledge of underlying mechanisms and select 
personalized treatments, aiming to improve immediate quality of life 
and promote long-term wellbeing.
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